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ABSTRACT
During the first year of the funding period 04/01/2011 until present, we have devoted the majority of our efforts towards obtaining pairs of mutant and functionally corrected telomerase-immortalized (hTERT) Fanconi anemia patient-derived fibroblast lines. Specifically, we have focused on the following FA complementation groups: FA-A, FA-G, and FA-D2. For the FA-D2 complementation group, we have obtained two pairs of mutant and corrected lines from collaborators. We have subsequently hTERT-immortalized these pairs during the funding period. For the FA-A complementation group, we had previously generated hTERT-immortalized mutant and corrected lines. During the funding period we have performed numerous functional assays, including mitomycin C cytotoxicity, clastogenicity, and G2-M accumulation assays, to confirm functional correction. For the FA-G complementation group, we purchased a primary FA-G line from Coriell Cell Repositories, hTERT-immortalized this line, generated a stable line expressing FANCG and are currently in the process of performing functional assays to confirm functional correction. In addition, for all of these mutant and corrected lines we are in the process of generating monoclonal cell populations to control for heterogeneity in pre-existing copy number variation within polyclonal cell populations. 
SUBJECT TERMS
Introduction
Fanconi anemia (FA) is a rare disease characterized by developmental defects, progressive bone marrow failure (BMF) and pronounced cancer susceptibility. The FA proteins and the major breast cancer susceptibility gene products BRCA1 and BRCA2 function cooperatively in the FA-BRCA pathway to repair damaged DNA. Recent studies have demonstrated that the FA-BRCA pathway plays an important role in the response of hematopoietic stem and progenitor cells to cellular stresses, and in particular oxidative stress caused by elevated levels of reactive oxygen species (ROS). In our research proposal, we have hypothesized that the FA-BRCA pathway may play an important role in the prevention of genome-wide de novo copy number variation. Chromosome copy number variation refers to gains or losses of large (>10 kb) genomic DNA segments. While copy number variation is a feature of normal genetic variation it is also strongly associated with genetic disease, including autism and psychiatric disorders. In addition, several recent studies have demonstrated that hematological malignancies show large numbers of de novo somatically acquired copy number variants (CNVs). As with all classes of mutation, an important role for de novo CNVs in cancer initiation and progression, as well as BMF, is highly likely. Importantly, the biological pathways that prevent de novo CNV formation, as well as the endogenous and exogenous agents that promote de novo CNV formation, remain largely unknown. We hypothesize that the FA-BRCA pathway, through its role in the suppression and repair of oxidative DNA damage, plays a central role in the prevention of genome-wide de novo CNVs. These mutational events are likely to be highly relevant to FA-associated BMF, myelodysplasia (MDS) and progression to acute myeloid leukemia (AML). The major goals of this research proposal are to systematically test the hypothesis that the FA-BRCA pathway plays a major role in the prevention of de novo pathogenic CNVs.
Body
With reference to our approved Statement of Work: In consultation with our collaborators in the Department of Human Genetics at the University of Michigan, we have decided that it is important to isolate monoclonal populations of FA-A hTERT and FA-A + FANCA hTERT cells prior to beginning the CNV analyses experimentation. All cells will have a measurable background level of CNVs and polyclonal cell populations will be mosaic for background CNV levels. For the purposes of our experiments, it is important to isolate genetically homogenous populations, with respect to CNV, prior to initiating our experiments. Therefore, de novo CNVs will be clearly distinguishable from pre-existing CNVs in the parental cell population. Thus, over the past few months we have sought to isolate monoclonal populations of FA-A hTERT and FA-A + FANCA hTERT cells. This has proven to be quite a challenge as in initial experiments the vast majority of clones, of both cell types, have failed to progress past the 10-20 cell clone size. However, with modifications to the serum composition and content of tissue culture growth medium we have made considerable progress over the past few weeks and are currently in the process of expanding multiple viable clones. A table summarizing our progress in isolating monoclonal cell populations of the FA-A hTERT and FA-A + FANCA hTERT cells is included in appendix 1.
FA-G complementation group:
At the start of the funding period we purchased the GM02361 FA-G patient derived line from Coriell Cell Repositories. We immortalized this line with hTERT and subsequently infected the FA-G hTERT cells with the murine moloney leukemia retroviral vectors pMMP-Empty or pMMP-FANCG. Recent immunoblotting experiments have confirmed re-expression of FANCG in the FA-G + FANCG hTERT cells (Figure 3) . We could not however detect FANCD2 protein expression by immunoblotting but could detect its paralog FANCI (Figure 3 Table 2 of the appendix.
FA-D2 complementation group:
We had previously obtained the PD733 primary FA-D2 line from the Fanconi Anemia Research Fund cell repository. We immortalized this line with hTERT to generate FA-D2 hTERT cells and subsequently infected these cells with pMMP-Empty or pMMP-FANCD2, to generate the FA-D2 hTERT and FA-D2 + FANCD2 hTERT lines. We had planned to use these lines for the CNV experiments. The PD733 FA-D2 line is reported to harbor compound heterozygous FANCD2 mutations: an intron 3 point mutation (IVS3-2 AT) and an exon 17 459 bp deletion mutation (g.22875_23333del459) (Kalb et al., 2007) . Early in the funding period we sought to confirm the presence of these mutations. Unfortunately, we could not detect the presence of the FANCD2 exon 17 459 bp deletion mutation in these cells and thus could not confirm the complementation group of this line. As an alternative approach we recently obtained two mutant and functionally corrected FA-D2 primary lines from Detlev Schlinder of the University of Wuerzburg in Germany. We have hTERT immortalized these lines and have recently confirmed FANCD2 protein re-expression in both of the FA-D2 + FANCD2 hTERT lines (Figure 4) . We are also currently in the process of performing DNA damage experiments with the FA-D2 hTERT and FA-D2 + FANCD2 hTERT cells to confirm restoration of DNA damageinducible FANCD2 and FANCI monoubiquitination in the FA-D2 + FANCD2 hTERT cells. In addition, similar to that described for the FA-A complementation group above, we are currently performing MMC cytotoxicity, clastogenicity and G2/M cell cycle stage accumulation assays to confirm functional correction of these cells. Furthermore, we are also currently in the process of isolating and expanding monoclonal populations of both pairs of FA-D2 hTERT and FA-D2 + FANCD2 hTERT cells. Unfortunately this is proving particularly challenging. In general, compared with other FA complementation groups, FA-D2 cells tend to have a more severe chromosomal instability phenotype (Garcia-Higuera et al., 2001; Reliene et al., 2010) , and this may be contributing to the difficulty in obtaining monoclonal cell populations.
Isolation of monoclonal cell populations: As described above, in consultation with our collaborators at the University of Michigan who routinely perform SNP-based CNV analysis, we have agreed that our CNV experiments need to be performed with genetically homogenous monoclonal cell populations. (Atkuri et al., 2007) . We believe that an increased oxidative burden may be contributing to our difficulties in isolating monoclonal cell populations. This may also be exacerbated in the case of FA, as it is well known that FA cells are particularly sensitive to reactive oxygen species (Du et al., 2008; Zhang et al., 2007) . To overcome this obstacle we have recently purchased a New Brunswick Galaxy 170R tri-gas incubator enabling us to grow cells at physiological oxygen concentrations. We anticipate that this will greatly improve our ability to isolate monoclonal populations of mutant and corrected FA hTERT cells.
Key Research Accomplishments
• 
Reportable Outcomes
The major reportable outcomes achieved during the first year of funding for this award are the development of multiple cell lines critical for our experimental approach, as described above.
Conclusion
Task 1 of our original Statement of Work was to develop several sets of mutant and functionally corrected hTERT-immortalized FA lines. We have made considerable progress in this endeavor. In addition, following consultation with our collaborators at the University of Michigan we have initiated experiments to isolate monoclonal populations of all of these lines. This is an arduous and time-consuming process, yet is essential for our planned CNV experiments (for rationale see above). While this has proven challenging thus far, we believe that we are on the verge of overcoming these challenges and will very soon have several monoclonal populations of mutant and functionally corrected FA-A, FA-G, and FA-D2 lines to directly test the hypothesis that the FA-BRCA pathway plays a major role in the prevention of de novo pathogenic CNVs.
